A Randomized, Double-blind, Placebo-controlled Phase III Study of Regorafenib Plus BSC Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy.

Trial Profile

A Randomized, Double-blind, Placebo-controlled Phase III Study of Regorafenib Plus BSC Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Regorafenib (Primary)
  • Indications Colorectal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms CORRECT
  • Sponsors Bayer
  • Most Recent Events

    • 12 Sep 2017 Results of exploratory analysis of baseline microsatellite instability status in colorectal cancer patients treated with regorafenib or placebo, were presented at the 42nd European Society for Medical Oncology Congress.
    • 01 Sep 2017 According to a Bayer media release, data regarding exploratory analysis of baseline microsatellite instability status in colorectal cancer patients will be presented at the European Society for Medical Oncology (ESMO) Congress in Sep 2017.
    • 02 Jun 2017 Results (n=505) of post hoc exploratory retrospective analysis assessing association between Hand-foot skin reaction (HFSR) and clinical outcomes, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top